1. Home
  2. JAGU vs ANVS Comparison

JAGU vs ANVS Comparison

Compare JAGU & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

JAGU

Jaguar Uranium Corp. Class A Common Shares

N/A

Current Price

$2.72

Market Cap

58.0M

Sector

N/A

ML Signal

N/A

Logo Annovis Bio Inc.

ANVS

Annovis Bio Inc.

HOLD

Current Price

$1.91

Market Cap

46.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JAGU
ANVS
Founded
2022
2008
Country
Canada
United States
Employees
3
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.0M
46.5M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
JAGU
ANVS
Price
$2.72
$1.91
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$13.50
AVG Volume (30 Days)
492.3K
1.2M
Earning Date
05-11-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
39.39
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.44
$1.36
52 Week High
$3.60
$5.50

Technical Indicators

Market Signals
Indicator
JAGU
ANVS
Relative Strength Index (RSI) 53.89 42.62
Support Level $2.14 $1.56
Resistance Level $2.94 $2.67
Average True Range (ATR) 0.44 0.19
MACD 0.08 0.01
Stochastic Oscillator 46.83 29.23

Price Performance

Historical Comparison
JAGU
ANVS

About JAGU Jaguar Uranium Corp. Class A Common Shares

Jaguar Uranium Corp is a uranium exploration and development company focused on uranium discoveries. The company is a junior miner engaged in uranium exploration. Its portfolio is comprised of two uranium exploration projects in Argentina and one uranium exploration project in Colombia. Its projects include the Berlin Project, the Laguna Project, and the Huemul Project. The company operates in one reportable segment which is the exploration and evaluation of mineral properties.

About ANVS Annovis Bio Inc.

Annovis Bio Inc is a late-stage clinical drug platform company addressing neurodegeneration, including Alzheimer's disease (AD) and Parkinson's disease (PD). The Company is developing its product candidate, buntanetap, a synthetically produced, orally administered, brain-penetrant small molecule designed to treat AD, PD, and potentially other chronic neurodegenerative diseases by inhibiting the synthesis of neurotoxic proteins and TDP43, which contribute to neurodegeneration and reduced axonal transport. Its pipeline includes buntanetap for chronic neurodegeneration, including AD, PD, and PDD, as well as in certain combination therapies, ANVS405 for acute neurodegeneration, and ANVS301 for AD.

Share on Social Networks: